Stimulatory effect of imeglimin on incretin secretion
Journal of Diabetes Investigation · 2023
DOI: 10.1111/jdi.14001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2023. Verfasst von Quan Yingyue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Incretins, Blood Glucose. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI, Sumitomo Pharma Co. Ltd..
Abstract (Originalsprache)
Aims/Introduction Imeglimin is a new antidiabetic drug structurally related to metformin. Despite this structural similarity, only imeglimin augments glucose‐stimulated insulin secretion (GSIS), with the mechanism underlying this effect remaining unclear. Given that glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) also enhance GSIS, we examined whether these incretin hormones might contribute to the pharmacological actions of imeglimin. Materials and Methods Blood glucose and plasma insulin, GIP, and GLP‐1 concentrations were measured during an oral glucose tolerance test (OGTT) performed in C57BL/6JJcl (C57BL/6) or KK‐Ay/TaJcl (KK‐Ay) mice after administration of a single dose of imeglimin with or without the dipeptidyl peptidase‐4 inhibitor sitagliptin or the GLP‐1 receptor antagonist exendin‐9. The effects of imeglimin, with or without GIP or GLP‐1, on GSIS were examined in C57BL/6 mouse islets.
Results
Imeglimin lowered blood glucose and increased plasma insulin levels during an OGTT in both C57BL/6 and KK‐Ay mice, whereas it also increased the plasma levels of GIP and GLP‐1 in KK‐Ay mice and the GLP‐1 levels in C57BL/6 mice. The combination of imeglimin and sitagliptin increased plasma insulin and GLP‐1 levels during the OGTT in KK‐Ay mice to a markedly greater extent than did either drug alone. Imeglimin enhanced GSIS in an additive manner with GLP‐1, but not with GIP, in mouse islets. Exendin‐9 had only a minor inhibitory effect on the glucose‐lowering action of imeglimin during the OGTT in KK‐Ay mice.
Conclusions
Our data suggest that the imeglimin‐induced increase in plasma GLP‐1 levels likely contributes at least in part to its stimulatory effect on insulin secretion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Laboratory of Animal Breeding and Genetics, Graduate School of Agriculture, Kyoto University, Kyoto, Japan.
- Laboratory of Animal Science, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.
ORCID-Profile: Kenji Sugawara, Norihide Yokoi, Susumu Seino, Wataru Ogawa
Förderung
- Japan Society for the Promotion of Science KAKENHI
- Sumitomo Pharma Co. Ltd.
Zitieren
APA
Yingyue, Q., Sugawara, K., Takahashi, H., Yokoi, N., Ohbayashi, K., Iwasaki, Y., Seino, S., & Ogawa, W. (2023). Stimulatory effect of imeglimin on incretin secretion. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14001
Vancouver
Yingyue Q, Sugawara K, Takahashi H, Yokoi N, Ohbayashi K, Iwasaki Y, et al. Stimulatory effect of imeglimin on incretin secretion. Journal of Diabetes Investigation. 2023. doi:10.1111/jdi.14001
BibTeX
@article{Yingyue2023,
author = {Yingyue, Quan and Sugawara, Kenji and Takahashi, Harumi and Yokoi, Norihide and Ohbayashi, Kento and Iwasaki, Yusaku and Seino, Susumu and Ogawa, Wataru},
title = {Stimulatory effect of imeglimin on incretin secretion},
journal = {Journal of Diabetes Investigation},
year = {2023},
doi = {10.1111/jdi.14001}
}
EUVIMED